Catalog No.
DVV03108
Expression system
Mammalian Cells
Species reactivity
Human immunodeficiency virus 1 (HIV-1)
Host species
Human
Isotype
IgG
Clonality
Monoclonal
Target
Envelope glycoprotein gp160, Env polyprotein, Surface protein gp120, SU, Glycoprotein 120, gp120, Transmembrane protein gp41, TM, Glycoprotein 41, gp41, env
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q03805
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Bispecific
Clone ID
GS-8588
Immunoinformatic-driven design and evaluation of multi-epitope mRNA vaccine targeting HIV-1 gp120., PMID:40433366
Vaccination of nonhuman primates elicits a broadly neutralizing antibody lineage targeting a quaternary epitope on the HIV-1 Env trimer., PMID:40339576
Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine Trial., PMID:38916429
Plasma Human Immunodeficiency Virus 1 Soluble Glycoprotein 120 Association With Correlates of Immune Dysfunction and Inflammation in Antiretroviral Therapy-Treated Individuals With Undetectable Viremia., PMID:38035854
Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120., PMID:37795976
Indoline CD4-mimetic compounds mediate potent and broad HIV-1 inhibition and sensitization to antibody-dependent cellular cytotoxicity., PMID:36961924
Myomedin replicas of gp120 V3 loop glycan epitopes recognized by PGT121 and PGT126 antibodies as non-cognate antigens for stimulation of HIV-1 broadly neutralizing antibodies., PMID:36569830
Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans., PMID:31999736
The glycan-mediated mechanism on the interactions of gp120 with CD4 and antibody: Insights from molecular dynamics simulation., PMID:28632942
Cross-Neutralization Activity of Single-Chain Variable Fragment (scFv) Derived from Anti-V3 Monoclonal Antibodies Mediated by Post-Attachment Binding., PMID:26902223
A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo., PMID:26516768
HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition., PMID:26180102
An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1., PMID:24614107
Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector., PMID:24098600
Molecular architecture of the uncleaved HIV-1 envelope glycoprotein trimer., PMID:23757493
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG., PMID:23661056
Antibodies to a superantigenic glycoprotein 120 epitope as the basis for developing an HIV vaccine., PMID:23089396
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1., PMID:20616233
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand., PMID:19843557
The differential binding and activity of PRO 2000 against diverse HIV-1 envelopes., PMID:19349871
Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry., PMID:17480119
Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: Potential for HIV-1 therapy., PMID:17157668
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial., PMID:17106277
Selection and characterization of an HIV-1 gp120-binding affibody ligand., PMID:16712522
HIV-1-mediated syncytium formation promotes cell-to-cell transfer of Tax protein and HTLV-I gene expression., PMID:16413627
CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis., PMID:16046522
Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial., PMID:15688279
Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp., PMID:15613479
Human immunodeficiency virus type 1 evades T-helper responses by exploiting antibodies that suppress antigen processing., PMID:15220439
Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point., PMID:15187026
HIV-1-infected patients with envelope-specific lymphoproliferation or long-term nonprogression lack antibodies suppressing glycoprotein 120 antigen presentation., PMID:14976603
Purified complexes of HIV-1 envelope glycoproteins with CD4 and CCR5(CXCR4): production, characterization and immunogenicity., PMID:14505910
In vivo efficacy of anti-glycoprotein 41, but not anti-glycoprotein 120, immunotoxins in a mouse model of HIV infection., PMID:12574398
Inhibitors of protein-disulfide isomerase prevent cleavage of disulfide bonds in receptor-bound glycoprotein 120 and prevent HIV-1 entry., PMID:12218051
High levels of antibodies to the CD4 binding domain of human immunodeficiency virus type 1 glycoprotein 120 are associated with faster disease progression., PMID:12134256
Role of N-glycans and SDF-1alpha on the coassociation of CD4 with CXCR4 at the plasma membrane of monocytic cells and blood lymphocytes., PMID:11943153
CTLA-4 upregulation during HIV infection: association with anergy and possible target for therapeutic intervention., PMID:11872994
Postattachment neutralization of a primary strain of HIV type 1 in peripheral blood mononuclear cells is mediated by CD4-specific antibodies but not by a glycoprotein 120-specific antibody that gives potent standard neutralization., PMID:11779352
A defined conformational epitope from the C4 domain of HIV type 1 glycoprotein 120: anti-cyclic C4 antibodies from HIV-positive donors magnify glycoprotein 120 suppression of interleukin 2 produced by T cells., PMID:11350667
Use of human CD4 transgenic mice for studying immunogenicity of HIV-1 envelope protein gp120., PMID:11305358
Anti-CD4-binding domain antibodies complexed with HIV type 1 glycoprotein 120 inhibit CD4+ T cell-proliferative responses to glycoprotein 120., PMID:10875615
Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination., PMID:10606091
A genetically engineered spleen necrosis virus-derived retroviral vector that displays the HIV type 1 glycoprotein 120 envelope peptide., PMID:10566890
HIV-induced T-cell syncytia release a two component T-helper cell chemoattractant composed of Nef and Tat., PMID:10547354
Sendai virus-based production of HIV type 1 subtype B and subtype E envelope glycoprotein 120 antigens and their use for highly sensitive detection of subtype-specific serum antibodies., PMID:10461831
Enhanced HIV type 1 neutralization by human anti-glycoprotein 120 monoclonal antibodies in the presence of monoclonal antibodies to lymphocyte function-associated molecule 1., PMID:10221529
Increased association of glycoprotein 120-CD4 with HIV type 1 coreceptors in the presence of complex-enhanced anti-CD4 monoclonal antibodies., PMID:10029247
The V3 region of gp120 is responsible for anti-HIV-1 activity of heparin sulphate., PMID:9918507
Investigations into the cross-reactivity of rabbit antibodies raised against nonhomologous pairs of synthetic peptides derived from HIV-1 gp120 proteins., PMID:9894846
The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein., PMID:9813203
For research use only. Not for human or drug use.
